Jiangsu Hengrui Medicine (600276) Q1 2026 earnings summary

Executive summary

• Achieved revenue of RMB 8.14 billion in Q1 2026, up 12.98% year-over-year; net profit attributable to shareholders reached RMB 2.28 billion, up 21.78% year-over-year.

• Innovative drug sales rose 25.75% to RMB 4.53 billion, accounting for 61.69% of pharmaceutical sales; non-oncology innovative drugs surged 92.13%.

• R&D investment totaled RMB 2.22 billion, with significant progress in new drug approvals and clinical trials.

Financial highlights

• Operating income: RMB 8.14 billion, up 12.98% year-over-year.

• Net profit attributable to shareholders: RMB 2.28 billion, up 21.78% year-over-year.

• Operating cash flow: RMB 786 million, up 41.66% year-over-year.

• Basic and diluted EPS: RMB 0.34, up 13.33% year-over-year.

• Total assets: RMB 71.29 billion, up 2.04% from year-end 2025.

Outlook and guidance

• Aims for over 30% annual growth in innovative drug sales, driven by new product launches and expanded indications.

• Expects continued optimization of revenue structure with a greater share from innovative drugs.